Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 臨床醫學研究所
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/581989
Title: Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B
Authors: Chien R.-N.
Peng C.-Y.
JIA-HORNG KAO 
Hu T.-H.
Lin C.-C.
Hu C.-T.
Chen C.-Y.
Hsieh T.-Y.
Lin H.-C.
Chuang W.-L.
Keywords: Chronic hepatitis B; Entecavir; Lamivudine; Patient adherence; Telbivudine
Issue Date: 2014
Journal Volume: 29
Journal Issue: 1
Start page/Pages: 185-192
Source: Journal of Gastroenterology and Hepatology (Australia)
Abstract: 
Background and Aims: Oral nucleos(t)ide analogs (NAs) are effective in suppressing hepatitis B virus (HBV) replication in treatment na?ve chronic hepatitis B (CHB) patients. However, little is known about the treatment modification and adherence on such patients with prolonged NA treatment. Methods: In this multicenter observational study, a total of 600 NA-na?ve Taiwanese CHB patients aged 16 years and older were enrolled. The 600 patients were retrospectively identified by their NA treatment history from August 2008 to July 2009; this cohort was prospectively followed up over 3 years. During the 3-year period, incidence of treatment modifications, reasons for modification, and rate of adherence were evaluated. Results: Among the 583 evaluable patients, the initial NA treatment included entecavir (ETV) in 468 patients, telbivudine (LdT) in 67, and lamivudine (LVD) in 48. During the 3-year treatment, 9.0% of ETV-treated patients, 38.8% of LdT-treated patients, and 54.2% of LVD-treated patients had treatment modification. The main reasons for treatment modification were fulfilling stopping criteria in the ETV group (40.5%) and virological breakthrough in both the LdT (61.5%) and LVD (46.2%) groups. The proportion of patients with adherence rate (>90%) at year 3 was 90.8% in the ETV group, 83.9% in the LdT group, and 83.9% in the LVD group. Conclusions: Treatment-na?ve CHB patients with a 3-year ETV treatment in Taiwan have the lower likelihood of treatment modification and better rate of adherence compared with those with LdT or LVD treatment. ? 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897607632&doi=10.1111%2fjgh.12416&partnerID=40&md5=3f4defb36088a136ef763ee8e427d3fe
https://scholars.lib.ntu.edu.tw/handle/123456789/581989
ISSN: 0815-9319
DOI: 10.1111/jgh.12416
SDG/Keyword: entecavir; lamivudine; telbivudine; virus DNA; adolescent; adult; aged; article; chronic hepatitis; demography; drug efficacy; female; follow up; hepatitis B; Hepatitis B virus; human; incidence; long term care; maintenance therapy; major clinical study; male; middle aged; observational study; patient compliance; priority journal; Taiwan; treatment modification; treatment outcome; treatment refusal; unspecified side effect; very elderly; young adult; chronic hepatitis B; entecavir; lamivudine; patient adherence; telbivudine; Administration, Oral; Adolescent; Adult; Antiviral Agents; Cohort Studies; Dihydropyridines; Female; Follow-Up Studies; Guanine; Hepatitis B; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Prospective Studies; Taiwan; Time Factors; Young Adult
[SDGs]SDG3
Appears in Collections:臨床醫學研究所

Show full item record

SCOPUSTM   
Citations

9
checked on Mar 13, 2023

WEB OF SCIENCETM
Citations

8
checked on Mar 12, 2023

Page view(s)

19
checked on Mar 23, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback